EpidStrategies’ scientists are recognized experts in the field of respiratory syncytial virus (RSV). Our RSV research program supported the newly-approved monoclonal antibody with… read more
ToxStrategies scientist Dr. Rayetta Henderson is among the authors of two new articles published by the journal Cannabis and Cannabinoid Research. Together, these… read more
ToxStrategies scientists have published a manuscript in the journal Regulatory Toxicology and Pharmacology reporting the outcome of a state-of-the-science assessment to develop recommendations… read more
We are thrilled to announce that Dr. Fernando Sampedro has joined ToxStrategies LLC, bringing his broad expertise and depth of experience to our Foods… read more
EpidStrategies, a Division of ToxStrategies LLC, is pleased to announce the addition of Dr. Michael Kelsh to our team, adding considerable depth to… read more
ToxStrategies scientists Marcie Wood, Ph.D. and Kirsten Mease, B.S. will be presenting at The Charles River Biotech Symposium – Biotechnology-Derived Therapeutics Perspectives on… read more
For more than a century, radiation health has been a concern for the public and for workers. However, the launch of the Hollywood… read more
In the United States, a new monoclonal antibody (nirsevimab; trade name: Beyfortus) was recently approved by the FDA and recommended by the CDC… read more
